ライフサイエンスコーパス: isosorbide

1 atenolol 100 mg was added to amlodipine and isosorbide 5-mononitrate 100 mg to diltiazem (Adizem XL)

2 mlodipine/atenolol and diltiazem (Adizem XL)/isosorbide 5-mononitrate on exercise and ambulatory myoc

3 e/atenolol superior to diltiazem (Adizem XL)/isosorbide 5-mononitrate.

4 eduction of portal pressure (propranolol and isosorbide-5-mononitrate; n = 95).

5 hydroformylation on olefinic derivatives of isosorbide and isomannide is shown by which a new carbon

6 Nifedipine, isosorbide, and nitroglycerin were further evaluated for

7 Finally, an intracoronary bolus of isosorbide dinitrate (1000 microgram) was given.

8 not SV dilated in response to adenosine and isosorbide dinitrate (all P<0.05, RA versus SV, percent

9 In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with red

10 ceived either 100 mg of sildenafil, 10 mg of isosorbide dinitrate (ISDN) or placebo during exercise o

11 creased overall mortality versus hydralazine/isosorbide dinitrate (p < 0.035) in V-HeFT II.

12 of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patien

13 Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced m

14 ing enzyme inhibitors and the combination of isosorbide dinitrate and hydralazine differs in black an

15 reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC

16 with greater impact of fixed combination of isosorbide dinitrate and hydralazine on the primary comp

17 We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional

18 ricle remodeling, outcomes and the impact of isosorbide dinitrate and hydralazine.

19 Isosorbide dinitrate and nitroglycerin markedly inhibite

20 Although the combined use of hydralazine and isosorbide dinitrate confers important clinical benefits

21 and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005.

22 ts in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligible), and an

23 sion was also observed in vivo in rats given isosorbide dinitrate in the drinking water, with a dose-

24 overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mostly white patient populat

25 in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs.

26 randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addi

27 was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placeb

28 The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therap

29 r in combination with nitroglycerin (NTG) or isosorbide dinitrate restores Ca(2+) cycling and contrac

30 combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the U.S. Food and D

31 placebo therapy in V-HeFT I, and hydralazine/isosorbide dinitrate was compared with enalapril in V-He

32 on fraction >35%, treatment with hydralazine/isosorbide dinitrate was compared with prazosin and plac

33 w responses to adenosine, acetylcholine, and isosorbide dinitrate were comparable.

34 ions that compared hydralazine hydrochloride-isosorbide dinitrate with placebo or with enalapril.

35 t failure who took hydralazine hydrochloride-isosorbide dinitrate with standard therapy experienced a

36 03 for acetylcholine and r=-0.62, P=0.05 for isosorbide dinitrate) but not in LITA (r=-0.18, P=0.63 f

37 63 for acetylcholine and r=-0.11, P=0.75 for isosorbide dinitrate).

38 n of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure

39 ockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants.

40 ethylenetriamine-NO and the organic nitrate, isosorbide dinitrate, the inhibitory effects of NO-aspir

41 d by selective infusion of acetylcholine and isosorbide dinitrate.

42 t infusions of adenosine, acetylcholine, and isosorbide dinitrate.

43 y and sudden death compared with hydralazine/isosorbide dinitrate.

44 heart failure when given concomitantly with isosorbide dinitrate.

45 Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in

46 Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved cli

47 whereas, more women developed headache after isosorbide mononitrate (27%) than after gemeprost (0%).

48 ly and significantly with increased doses of isosorbide mononitrate (but not placebo).

49 igned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg on

50 men taking the nitric oxide (NO) donor drugs isosorbide mononitrate (ISMN) or glyceryl trinitrate (GT

51 agonist amlodipine (10 mg once daily) versus isosorbide mononitrate (ISMN, 50 mg once daily) on poste

52 gned to receive before surgery, per vaginam, isosorbide mononitrate 40 mg or 80 mg, or the prostaglan

53 nal administration of the nitric oxide donor isosorbide mononitrate can induce effective ripening of

54 Isosorbide mononitrate could be used as an alternative t

55 oxide donors such as glyceryl trinitrate or isosorbide mononitrate could be used to deliver nitric o

56 ntraoperative blood loss with either dose of isosorbide mononitrate did not differ from those in a co

57 During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the

58 essed during a 14-day period before starting isosorbide mononitrate or placebo (n=110).

59 We compared the effect of isosorbide mononitrate or placebo on daily activity in s

60 More women remained symptom-free after isosorbide mononitrate than after gemeprost (28/44 [64%]

61 Pretreatment with isosorbide mononitrate to ripen the cervix before first-

62 d a preserved ejection fraction who received isosorbide mononitrate were less active and did not have

63 In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo gro

64 compared with 3% and 0%, respectively, after isosorbide mononitrate, whereas, more women developed he

65 6-minute walk distance, and NT-proBNP) with isosorbide mononitrate.

66 act was also suppressed by administration of isosorbide or theophylline in the drinking water.